Akari Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DICICCO WENDY F
Akari Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jacques Rachelle Suzanne
Akari Therapeutics | D: Filing D
Akari Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ray Prudo, M.D.(26.4%),RPC Pharma Limited(6.1%), etc.
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Jacques Rachelle Suzanne
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer DICICCO WENDY F
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Patel Samir Rashmikant
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Hashad Mohamed Wa'el Ahmed
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Prudo-Chlebosz Raymond
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Grissinger Michael
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Director WILLIAMS DONALD A
Akari Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ray Prudo, M.D.(21.8%),RPC Pharma Limited(7.2%), etc.
Akari Therapeutics | D: Filing D
Akari Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ray Prudo, M.D.(22.7%),RPC Pharma Limited(7.9%), etc.
Akari Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Samir R. Patel(9.9%)
Akari Therapeutics | D: Filing D
Akari Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Samir R. Patel(6.2%)
Akari Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ray Prudo, M.D.(18%),RPC Pharma Limited(16.8%), etc.
Akari Therapeutics | SC 13D/A: Schedule filed to report acquisition of beneficial ownership of more than 5% of a class of equity securities (Amendment)
Akari Therapeutics | D: Filing D
No Data